drugset / Trial / NCT05673187
Adagrasib in Patients With KRASG12C-mutant NSCLC Who Are Elderly or Have Poor Performance Status
Phase 2
Active not recruiting
68 enrolled
ETOP IBCSG Partners Foundation
Mirati Therapeutics Inc. · collab
NaSingle-groupOpen-labelTreatment
Summary
ADEPPT is an international, multicentre, single-arm phase II trial. The protocol treatment consists of adagrasib, which is administered at a dose of 600 mg orally, twice daily until progression or unacceptable toxicity.The primary objective of this trial is to assess the clinical efficacy of adagrasib treatment, in terms of objective response, in patients with KRASG12C-mutant NSCLC, including the elderly (≥70 years) or patients with poor performance status (ECOG PS=2).
Timeline
- Start
- 2023-06-12
- Primary completion
- 2025-07-28
- Completion
- 2026-07
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Adagrasib | Small molecule | 600 mg | Oral |